Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
Benzinga's M&A Chatter for Wednesday February 25, 2015
Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More (Seeking Alpha)
Related ZIOP
Friday's #PreMarket Movers: JC Penney Down Following Q4 Earnings
Biotech Stocks Moving Higher
Intrexon: Back-End Economics Could Generate Huge Upside (Seeking Alpha)

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Jan 2015Cowen & CompanyUpgradesMarket PerformOutperform
Dec 2014Morgan StanleyUpgradesUnderweightEqualweight
May 2014JefferiesUpgradesHoldBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters